After a blistering performance based on the success of its weight-loss treatments Mounjaro and Zepbound, Eli Lilly & Company (NYSE:LLY) stock has been trading sideways for the last five weeks as the company struggles to keep pace with demand for the drugs. Eli Lilly shares have climbed 162% since the launch of Mounjaro in May 2022. Since mid-February, however, the shares have stalled, albeit around record levels. The sideways move could be attributed to a lack of availability of its two latest blockbusters. Sales of its new products, launched since 2022, that include both Mounjaro and its sist…
